Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company), a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology, based on its proprietary technological platform DOS47, is pleased to announce that the Company has closed the private placement of 15,666,666 common shares of the Company (“Common Share”) at a price of $0.15 per Common Share for gross proceeds of CAD$2,350,000 (the “Offering”).
NR20240531_Closing of Private Placement of Common Shares